The Heterogeneous Effect of Atrial Fibrillation Screening: A Secondary Analysis of the VITAL-AF Trial.
Sachin J ShahJay M IyerLeila AghaYuchiao ChangJeffrey M AshburnerSteven J AtlasDavid D McManusPatrick T EllinorSteven A LubitzDaniel E SingerPublished in: medRxiv : the preprint server for health sciences (2024)
In a secondary analysis of the VITAL-AF trial, we identified a small subgroup where one-time screening was associated with increased AF diagnoses using an effect-based approach. In this study, predicted AF risk was a poor proxy for predicted screening efficacy. These data caution against the assumption that high AF risk is necessarily correlated with high screening efficacy.
Keyphrases
- atrial fibrillation
- left atrial
- catheter ablation
- oral anticoagulants
- phase iii
- left atrial appendage
- clinical trial
- direct oral anticoagulants
- heart failure
- percutaneous coronary intervention
- phase ii
- machine learning
- randomized controlled trial
- acute coronary syndrome
- coronary artery disease
- open label
- electronic health record
- deep learning
- mitral valve